News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Scancell has reported preliminary immunogenicity data from its Phase 1 COVIDITY clinical trial: with the plasmid DNA COVID-19 vaccine candidates inducing immune responses when delivered via needle-free tech.
Genentech is to build a new biologics facility at its Oceanside, California campus that it says will be at the forefront of next-generation manufacturing and environmentally sustainable production for small-batch commercial biologics.
Roche’s ophthalmic disease therapy, Vabysmo, has met its primary endpoint in two global Phase 3 trials.
Pfizer and BioNTech have started a Phase 1/2 trial in the US to assess mRNA vaccine candidates against shingles.